Advertisement

Decision Pathways in Breast Cancer Management

  • Adnan Aydiner
  • Abdullah Igci
  • Neslihan Cabioglu
  • Leyla Ozer
  • Fatma Sen
  • Serkan Keskin
  • Mahmut Muslumanoglu
  • Hasan Karanlik
  • Kamuran Arslan Ibis
  • Seden Kucucuk
  • Maktav Dincer
  • Ekrem Yavuz
  • Sitki Tuzlali
  • Atilla Soran
Chapter

Abstract

This chapter reviews substantial new evidence on locoregional and systemic therapies for early and advanced breast cancer and in situ carcinoma. In breast cancer, the treatment strategy is chosen based on the features and biology of the tumor and on the patient’s age, general health status and personal preferences. The decision options are based on the best evidence-based recommendations. The decision process is based on comprehensive guidelines that elaborate the current sequential treatment options and interventions for breast cancer patients in detail. This information does not cover all possibilities in clinical decision-making. This chapter comprises decision pathways outlining the step-by-step clinical decision-making process for patient management.

Keywords

Breast cancer Decision pathways Chemotherapy Radiotherapy Surgery Invasive cancer In situ cancer Pregnancy Paget Cystosarcoma phyllodes 

References

  1. 1.
    NCCN guidelines for treatment of cancer by site. v.1.2018. Breast Cancer. www.nccn.org.
  2. 2.
    Morrow M, Van Zee KJ, Solin LJ, Houssami N, Chavez-MacGregor M, Harris JR, et al. Society of Surgical Oncology–American Society for Radiation Oncology–American Society of Clinical Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in ductal carcinoma in situ. J Clin Oncol. 2016;34:4040–6.CrossRefGoogle Scholar
  3. 3.
    Curigliano G, Burstein HJ, Winer EP, Gnant M, Dubsky P, Loibl S, et al. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann Oncol. 2017;28(8):1700–12.CrossRefGoogle Scholar
  4. 4.
    Visvanathan K, Hurley P, Bantug E, Brown P, Col NF, Cuzick J, et al. Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2013;31:2942–62.CrossRefGoogle Scholar
  5. 5.
    Aydiner A, Sen F, Karanlik H, Aslay I, Dincer M, İgci A. A review of local and systemic therapy in breast cancer. In: Aydiner A, İğci A, Soran A, editors. Breast disease, vol. II. Switzerland: Springer; 2016. p. 731–64.CrossRefGoogle Scholar
  6. 6.
    Guidelines of the AGO breast committee. Version 17.1.0. https://www.ago-online.de/en/guidelines-mamma/april-2017/. April 2017.
  7. 7.
    Margolese RG, Cecchini RS, Julian TB, Ganz PA, Costantino JP, et al. Primary results, NRG Oncology/NSABP B-35: a clinical trial of anastrozole (A) versus tamoxifen (tam) in postmenopausal patients with DCIS undergoing lumpectomy plus radiotherapy. J Clin Oncol. 2015;33(Suppl):abstr LBA500.CrossRefGoogle Scholar
  8. 8.
    Forbes JF, Sestak I, Howell A, Bonanni B, Bundred N, Levy C, et al. Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial. Lancet. 2016;387(10021):866–73.CrossRefGoogle Scholar
  9. 9.
    Lyman GH, Somerfield MR, Bosserman LD, Perkins CL, Weaver DL, Giuliano AE. Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2016;35:561–4.CrossRefGoogle Scholar
  10. 10.
    Giuliano AE, Mc Call LM, Beitsch PD, Whit PW, Morrow M, Blumencranz PW, et al. ACOSOGZ0011: a randomized trial of axillary node dissection in women with clinical T1-2 N0M0 breast cancer who have a positive sentinel node. J Clin Oncol. 2010;28(18):CRA 506.CrossRefGoogle Scholar
  11. 11.
    Bouughey JC, Suman VJ, Mittendorf EA, Ahrendt GM, Wilke LG, Taback B, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA. 2013;310:1455–61.CrossRefGoogle Scholar
  12. 12.
    Senkus E, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rutgers E, Zackrisson S, Cardoso F, et al. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl 5):v8–v30.CrossRefGoogle Scholar
  13. 13.
    Kuehn T, Bauerfeind I, Fehm T, Fleige B, Hausschild M, Helms G, et al. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet. 2013;14:609–18.CrossRefGoogle Scholar
  14. 14.
    Giuliano AE, Hunt KK, Ballman KV, Beitsch PD, Whitworth PW, Blumencranz PW, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA. 2011;305(6):569–75.CrossRefGoogle Scholar
  15. 15.
    Giuliano AE, Ballman KV, McCall L, Beitsch PD, Brennan MB, Kelemen PR, et al. Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (Alliance) randomized clinical trial. JAMA. 2017;318(10):918–26.CrossRefGoogle Scholar
  16. 16.
    Boileau JF, Poirier B, Basik M, Holloway CM, Gaboury L, Sideris L, et al. Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study. J Clin Oncol. 2015;33(3):258–64.CrossRefGoogle Scholar
  17. 17.
    Mamtani A, Barrio AV, King TA, Van Zee KJ, Plitas G, Pilewskie M, et al. How often does neoadjuvant chemotherapy avoid axillary dissection in patients with histologically confirmed nodal metastases? Results of a prospective study. Ann Surg Oncol. 2016;23(11):3467–74.CrossRefGoogle Scholar
  18. 18.
    Moo T, Edelweiss E, Hajiyeva S, Stempel M, Raiss M, Barrio AV. Is low-volume disease in the sentinel node after neoadjuvant chemotherapy an indication for axillary dissection. In: Society for Surgical Oncology (SSO) annual cancer symposium, Chicago; 2018(abstract 47).Google Scholar
  19. 19.
    De La Cruz L, Moody AM, Tappy EE, Blankenship SA, Hecht EM. Overall survival, disease-free survival, local recurrence, and nipple-areolar recurrence in the setting of nipple-sparing mastectomy: a meta-analysis and systematic review. Ann Surg Oncol. 2015;22(10):3241–9.CrossRefGoogle Scholar
  20. 20.
    Moran MS, Schnitt SJ, Giuliano AE, Harris JR, Khan SA, Horton J, et al. Society of Surgical Oncology-American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer. Int J Radiat Oncol Biol Phys. 2014;88:553–64.CrossRefGoogle Scholar
  21. 21.
    Coates AS, Winer EP, Goldhirsch A, Gelber RD, Gnant M, et al. Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol. 2015;26:1533–46.CrossRefGoogle Scholar
  22. 22.
    Wolff AC, Hammond MEH, Allison KH, Harvey BE, Mangu PB, Bartlett JMS, et al. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline focused update. J Clin Oncol. 2018.  https://doi.org/10.1200/JCO.2018.77.8738.CrossRefGoogle Scholar
  23. 23.
    Burstein HJ, Temin S, Anderson H, Buchholz TA, Davidson NE, Gelmon KE, et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American Society of Clinical Oncology clinical practice guideline focused update. J Clin Oncol. 2014;32(21):2255–69.CrossRefGoogle Scholar
  24. 24.
    von Minckwitz G, Procter M, de Azambuja E, Zardavas D, Benyunes M, Viale G, et al. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. N Engl J Med. 2017;377(2):122–31.CrossRefGoogle Scholar
  25. 25.
    Krop I, Ismaila N, Andre F, Bast RC, Barlow W, Collyar DE, et al. Biomarkers to guide decisions on adjuvant systemic therapy for women with early stage invasive breast cancer: American Society of Clinical Oncology clinical practice guideline focused update. J Clin Oncol. 2017;35(24):2838–47.CrossRefGoogle Scholar
  26. 26.
    Denduluri N, Chavez-MacGregor M, Telli ML, Eisen A, Graff SL, Hassett MJ, et al. Selection of optimal adjuvant chemotherapy and targeted therapy for early breast cancer: ASCO clinical practice guideline focused update. J Clin Oncol. 2018.  https://doi.org/10.1200/JCO.2018.78.8604.CrossRefGoogle Scholar
  27. 27.
    Burstein HJ, Lacchetti C, Anderson H, Buchholz TA, Davidson NE, Gelmon KE, et al. Adjuvant endocrine therapy for women with hormone receptor–positive breast cancer: American Society of Clinical Oncology clinical practice guideline update on ovarian suppression. J Clin Oncol. 2016;34:1689–701.CrossRefGoogle Scholar
  28. 28.
    Henry NL, Somerfield MR, Abramson VG, Allison KH, Anders CK, Diana T, et al. Role of patient and disease factors in adjuvant systemic therapy decision making for early-stage, operable breast cancer: American Society of Clinical Oncology endorsement of cancer care ontario guideline recommendations. J Clin Oncol. 2016;34:2303–11.CrossRefGoogle Scholar
  29. 29.
    Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, et al. Prospective validation of a 21-gene expression assay in breast cancer. N Engl J Med. 2015;373:2005–14.CrossRefGoogle Scholar
  30. 30.
    Gluz O, Nitz UA, Christgen M, Kates RE, Shak S, Clemens M, et al. West German Study Group Phase III PlanB Trial: first prospective outcome data for the 21-gene recurrence score assay and concordance of prognostic markers by central and local pathology assessment. J Clin Oncol. 2016;34:2341–9.CrossRefGoogle Scholar
  31. 31.
    Cardoso F, van ’t Veer LJ, Bogaerts J, Slaets L, Viale G, Delaloge S, MINDACT Investigators. 70-gene signature as an aid to treatment decisions in early-stage breast cancer. N Engl J Med. 2016;375(8):717–29.CrossRefGoogle Scholar
  32. 32.
    Tolaney SM, Barry WT, Dang CT, Yardley DA, Moy B, Marcom PK, et al. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. N Engl J Med. 2015;372:134–41.CrossRefGoogle Scholar
  33. 33.
    Zhou Q, Yin W, Du Y, Lu J. For or against adjuvant trastuzumab for pT1a-bN0M0 breast cancer patients with HER2-positive tumors: a meta-analysis of published literatures. PLoS One. 2014;9(1):e83646.CrossRefGoogle Scholar
  34. 34.
    Gerber B, Ortmann O. Prevention of Early Menopause Study (POEMS): is it possible to preserve ovarian function by gonadotropin releasing hormone analogs (GnRHa)? Arch Gynecol Obstet. 2014;290:1051–3.CrossRefGoogle Scholar
  35. 35.
    Francis PA, Regan MM, Fleming GF, Láng I, Ciruelos E, Bellet M, et al. Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med. 2015;372:436–46.CrossRefGoogle Scholar
  36. 36.
    Park JW, Liu MC, Yee D, Yau C, van ’t Veer LJ, Symmans WF, I-SPY 2 Investigators, et al. Adaptive randomization of neratinib in early breast cancer. N Engl J Med. 2016;375(1):11–22.CrossRefGoogle Scholar
  37. 37.
    Goss PE, Ingle JN, Pritchard KI, Robert NJ, Muss H, Gralow J, et al. Extending aromatase-inhibitor adjuvant therapy to 10 years. N Engl J Med. 2016;375(3):209–19.CrossRefGoogle Scholar
  38. 38.
    Sikov WM, Berry DA, Perou CM, Singh B, Cirrincione CT, Tolaney SM, et al. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). J Clin Oncol. 2015;33(1):13–21.CrossRefGoogle Scholar
  39. 39.
    Del Mastro L, De Placido S, Bruzzi P, De Laurentiis M, Boni C, Cavazzini G, et al. Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2×2 factorial, randomised phase 3 trial. Lancet. 2015;385(9980):1863–72.CrossRefGoogle Scholar
  40. 40.
    Foukakis T, von Minckwitz G, Bengtsson NO, Brandberg Y, Wallberg B, Fornander T, et al. Effect of tailored dose-dense chemotherapy vs standard 3-weekly adjuvant chemotherapy on recurrence-free survival among women with high-risk early breast cancer: a randomized clinical trial. JAMA. 2016;316(18):1888–96.CrossRefGoogle Scholar
  41. 41.
    Gianni L, Pienkowski T, Im YH, Tseng LM, Liu MC, Lluch A, et al. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. Lancet Oncol. 2016;17(6):791–800.CrossRefGoogle Scholar
  42. 42.
    Joensuu H, Kellokumpu-Lehtinen PL, Huovinen R, Jukkola-Vuorinen A, Tanner M, Kokko R, et al. Adjuvant capecitabine in combination with docetaxel, epirubicin, and cyclophosphamide for early breast cancer: the randomized clinical FinXX trial. JAMA Oncol. 2017;3(6):793–800.CrossRefGoogle Scholar
  43. 43.
    Masuda N, Lee SJ, Ohtani S, Im YH, Lee ES, Yokota I, et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med. 2017;376(22):2147–59.CrossRefGoogle Scholar
  44. 44.
    Pagani O, Regan MM, Francis PA, TEXT and SOFT Investigators, International Breast Cancer Study Group. Exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med. 2014;371(14):1358–9.PubMedGoogle Scholar
  45. 45.
    Whelan TJ, Olivotto IA, Parulekar WR, Ackerman I, Chua BH, Nabid A, et al. Regional nodal irradiation in early-stage breast cancer. N Engl J Med. 2015;373(4):307–1.CrossRefGoogle Scholar
  46. 46.
    Strnad V, Ott OJ, Hildebrandt G, Kauer-Dorner D, Knauerhase H, Major T, Groupe Europe´en de Curiethe´rapie of European Society for Radiotherapy and Oncology (GEC-ESTRO), et al. 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Lancet. 2016;387(10015):229–38.CrossRefGoogle Scholar
  47. 47.
    Correa C, Harris EE, Leonardi MC, Smith BD, Taghian AG, Thompson AM, et al. Accelerated partial breast irradiation: executive summary for the update of an ASTRO evidence-based consensus statement. Pract Radiat Oncol. 2017;7:73–9.CrossRefGoogle Scholar
  48. 48.
    Bartelink H, Maingon P, Poortmans P, Weltens C, Fourquet A, Jager J, et al. Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial. Lancet Oncol. 2015;16(1):47–56.CrossRefGoogle Scholar
  49. 49.
    Bane AL, Whelan TJ, Pond GR, Parpia S, Gohla G, Fyles AW, et al. Tumor factors predictive of response to hypofractionated radiotherapy in a randomized trial following breast conserving therapy. Ann Oncol. 2014;25:992–8.CrossRefGoogle Scholar
  50. 50.
    Marta GN, Macedo CR, Carvalho Hde A, Hanna SA, da Silva JL, Riera R. Accelerated partial irradiation for breast cancer: systematic review and meta-analysis of 8653 women in eight randomized trials. Radiother Oncol. 2015;114:42–9.CrossRefGoogle Scholar
  51. 51.
    Budach W, Kammers K, Boelke E, Matuschek C. Adjuvant radiotherapy of regional lymph nodes in breast cancer—a meta-analysis of randomized trials. Radiat Oncol. 2013;8:267.CrossRefGoogle Scholar
  52. 52.
    Bellon JR, Golshan M, Solin LJ. Controversies in radiation oncology for early-stage breast cancer. Ann Surg Oncol. 2015;22:3213.CrossRefGoogle Scholar
  53. 53.
    Recht A, Comen EA, Fine RE, Fleming GF, Hardenbergh PH, Ho AY, et al. Postmastectomy radiotherapy: an American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of surgical oncology focused guideline update. J Clin Oncol. 2016;34:4431–42.CrossRefGoogle Scholar
  54. 54.
    Vrieling C, van Werkhoven E, Maingon P, Poortmans P, Weltens C, Fourquet A, et al. Prognostic factors for local control in breast cancer after long-term follow-up in the EORTC boost vs no boost trial: a randomized clinical trial. JAMA Oncol. 2017;3(1):42–8.CrossRefGoogle Scholar
  55. 55.
    Poortmans PM, Collette S, Kirkove C, Van Limbergen E, Budach V, Struikmans H, et al. Internal mammary and medial supraclavicular irradiation in breast cancer. N Engl J Med. 2015;373(4):317–27.CrossRefGoogle Scholar
  56. 56.
    Ataseven B, Lederer B, Blohmer JU, Denkert C, Gerber B, Heil J, et al. Impact of multifocal or multicentric disease on surgery and locoregional, distant and overall survival of 6,134 breast cancer patients treated with neoadjuvant chemotherapy. Ann Surg Oncol. 2015;22(4):1118–27.CrossRefGoogle Scholar
  57. 57.
    Santoro S, Loreti A, Cavaliere F, Costarelli L, La Pinta M, Manna E, et al. Neoadjuvant chemotherapy is not a contraindication for nipple sparing mastectomy. Breast. 2015;24(5):661–6.CrossRefGoogle Scholar
  58. 58.
    Gnant M, Pfeiler G, Dubsky PC, Hubalek M, Greil R, Jakesz R, et al. Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2015;386(9992):433–43.CrossRefGoogle Scholar
  59. 59.
    Gnant M, Mlineritsch B, Schippinger W, Luschin-Ebengreuth G, Pöstlberger S, Menzel C, et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med. 2009;360(7):679–91.CrossRefGoogle Scholar
  60. 60.
    Dhesy-Thind S, Fletcher GG, Blanchette PS, Clemons MJ, Dillmon MS, Frank ES, et al. Use of adjuvant bisphosphonates and other bone-modifying agents in breast cancer: a Cancer Care Ontario and American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2017;35:2062–81.CrossRefGoogle Scholar
  61. 61.
    Rugo HS, Olopade OI, DeMichele A, Yau C, van ’t Veer LJ, Buxton MB, et al. Adaptive randomization of veliparib-carboplatin treatment in breast cancer. N Engl J Med. 2016;375(1):23–34.CrossRefGoogle Scholar
  62. 62.
    Untch M, Jackisch C, Schneeweiss A, Conrad B, Aktas B, Denkert C, et al. Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, phase 3 trial. Lancet Oncol. 2016;17(3):345–56.CrossRefGoogle Scholar
  63. 63.
    Colleoni M, Gray KP, Gelber S, Láng I, Thürlimann B, Gianni L, et al. Low-dose oral cyclophosphamide and methotrexate maintenance for hormone receptor-negative early breast cancer: International Breast Cancer Study Group Trial 22-00. J Clin Oncol. 2016;34(28):3400–8.CrossRefGoogle Scholar
  64. 64.
    Curigliano G, Gómez Pardo P, Meric-Bernstam F, Conte P, Lolkema MP, Beck JT, et al. Ribociclib plus letrozole in early breast cancer: a presurgical, window-of-opportunity study. Breast. 2016;28:191–8.CrossRefGoogle Scholar
  65. 65.
    Ma CX, Gao F, Luo J, Northfelt DW, Goetz M, Forero A, et al. NeoPalAna: neoadjuvant palbociclib, a cyclin-dependent kinase 4/6 inhibitor, and anastrozole for clinical stage 2 or 3 estrogen receptor-positive breast cancer. Clin Cancer Res. 2017;23(15):4055–65.CrossRefGoogle Scholar
  66. 66.
    Dawood S, Merajver SD, Viens P, Vermeulen PB, Swain SM, Buchholz TA, et al. International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment. Ann Oncol. 2011;22:515–23.CrossRefGoogle Scholar
  67. 67.
    Partridge AH, Rumble B, Carey LA, Come SE, Davidson NE, Leo AD, et al. Chemotherapy and targeted therapy for women with human epidermal growth factor receptor 2–negative (or unknown) advanced breast cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2014;32:3307–29.CrossRefGoogle Scholar
  68. 68.
    Giordano SH, Temin S, Kirshner JJ, Chandarlapaty S, Crews JR, Davidson NE, et al. Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: ASCO clinical practice guideline update. J Clin Oncol. 2018;36  https://doi.org/10.1200/JCO.2018.79.2697.CrossRefGoogle Scholar
  69. 69.
    Cardoso F, Costa A, Senkus E, Aapro M, André F, Barrios CH, et al. 3rd ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 3). Ann Oncol. 2017;28(1):16–33.PubMedGoogle Scholar
  70. 70.
    Goetz MP, Toi M, Campone M, Sohn J, Paluch-Shimon S, Huober J, et al. MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol. 2017;35(32):3638–46.CrossRefGoogle Scholar
  71. 71.
    Slamon DJ, Neven P, Chia S, Fasching PA, De Laurentiis M, Im SA, et al. Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3. J Clin Oncol. 2018;3:JCO2018789909.  https://doi.org/10.1200/JCO.2018.78.9909. [Epub ahead of print]CrossRefGoogle Scholar
  72. 72.
    Nanda R, Chow LQ, Dees EC, Berger R, Gupta S, Geva R, et al. Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study. J Clin Oncol. 2016;34(21):2460–7.CrossRefGoogle Scholar
  73. 73.
    Finn RS, Martin M, Rugo HS, Jones S, Im SA, Gelmon K, et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med. 2016;375(20):1925–36.CrossRefGoogle Scholar
  74. 74.
    Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med. 2016;375(18):1738–48.CrossRefGoogle Scholar
  75. 75.
    Perez EA, Barrios C, Eiermann W, Toi M, Im YH, Conte P, et al. Trastuzumab emtansine with or without pertuzumab versus trastuzumab plus taxane for human epidermal growth factor receptor 2-positive, advanced breast cancer: primary results from the phase III MARIANNE study. J Clin Oncol. 2017;35(2):141–8.CrossRefGoogle Scholar
  76. 76.
    Badwe R, Hawaldar R, Nair N, Kaushik R, Parmar V, Siddique S, et al. Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: an open-label randomised controlled trial. Lancet Oncol. 2015;16(13):1380–8.CrossRefGoogle Scholar
  77. 77.
    Soran A, Ozmen V, Ozbas S, Karanlik H, Muslumanoglu M, Igci A, et al. Randomized trial comparing resection of primary tumor with no surgery in stage IV breast cancer at presentation: protocol MF07-01. Ann Surg Oncol. 2018.  https://doi.org/10.1245/s10434-018-6494-6. [Epub ahead of print].CrossRefGoogle Scholar
  78. 78.
    Piccart M, Hortobagyi GN, Campone M, Pritchard KI, Lebrun F, Ito Y, et al. Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†. Ann Oncol. 2014;25:2357–62.CrossRefGoogle Scholar
  79. 79.
    Finn RS, Crown JP, Lang I, Boer K, Bondarenko IM, Kulyk SO, et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol. 2015;16:25–35.CrossRefGoogle Scholar
  80. 80.
    Cristofanilli M, Turner NC, Bondarenko I, Ro J, Im SA, Masuda N, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol. 2016;17(4):425–39.CrossRefGoogle Scholar
  81. 81.
    Turner NC, Ro J, André F, Loi S, Verma S, Iwata H, et al. Palbociclib in hormone-receptor–positive advanced breast cancer. N Engl J Med. 2015.  https://doi.org/10.1056/NEJMoa1505270.CrossRefGoogle Scholar
  82. 82.
    Rugo HS, Rumble RB, Macrae E, Barton DL, Connolly HK, Dickler MN, et al. Endocrine therapy for hormone receptor–positive metastatic breast cancer: American Society of Clinical oncology guideline. J Clin Oncol. 2016;34:3069–103.CrossRefGoogle Scholar
  83. 83.
    Jerusalem G, Mariani G, Ciruelos EM, Martin M, Tjan-Heijnen VC, Neven P, et al. Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer progressing on prior non-steroidal aromatase inhibitors: primary results of a phase IIIb, open-label, single-arm, expanded-access multicenter trial (BALLET). Ann Oncol. 2016;27(9):1719–25.CrossRefGoogle Scholar
  84. 84.
    Kurian AW, Hare EE, Mills MA, Kingham KE, McPherson L, Whittemore AS, et al. Clinical evaluation of a multiple-gene sequencing panel for hereditary cancer risk assessment. J Clin Oncol. 2014;32(19):2001–9.CrossRefGoogle Scholar
  85. 85.
    Rageth CJ, O’Flynn EA, Comstock C, Kurtz C, Kubik R, Madjar H, et al. First International Consensus Conference on lesions of uncertain malignant potential in the breast (B3 lesions). Breast Cancer Res Treat. 2016;159:203–13.CrossRefGoogle Scholar
  86. 86.
    Strode M, Khoury T, Mangieri C, Takabe K. Update on the diagnosis and management of malignant phyllodes tumors of the breast. Breast. 2017;33:91–6.CrossRefGoogle Scholar
  87. 87.
    Li YJ, Huang XE, Zhou XD. Local breast cancer recurrence after mastectomy and breast-conserving surgery for Paget’s disease: a meta-analysis. Breast Care. 2014;9(6):431–4.CrossRefGoogle Scholar
  88. 88.
    Shafique MR, Lee MC, Han HS. Treatment of the pregnant patient with breast cancer. South Med J. 2017;110(10):627–31.CrossRefGoogle Scholar
  89. 89.
    Mir O, Berveiller P, Goffinet F, Treluyer JM, Serreau R, Goldwasser F, et al. Taxanes for breast cancer during pregnancy: a systematic review. Ann Oncol. 2010;21:425–6.CrossRefGoogle Scholar
  90. 90.
    Garcia-Gonzalez J, Cueva J, Lamas MJ, Curiel T, Graña B, López-López R. Paclitaxel and cisplatin in the treatment of metastatic non-small-cell lung cancer during pregnancy. Clin Transl Oncol. 2008;10:375–6.CrossRefGoogle Scholar
  91. 91.
    Bader AA, Schlembach D, Tamussino KF, Pristauz G, Petru E. Anhydramnios associated withadministration of trastuzumab and paclitaxel for metastatic breast cancer during pregnancy. Lancet Oncol. 2007;8:79–81.CrossRefGoogle Scholar
  92. 92.
    Amant F, Deckers S, Van Calsteren K, Loibl S, Halaska M, Brepoels L, et al. Breast cancer in pregnancy: recommendations of an international consensus meeting. Eur J Cancer. 2010;46:3158–68.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Adnan Aydiner
    • 1
  • Abdullah Igci
    • 2
  • Neslihan Cabioglu
    • 3
  • Leyla Ozer
    • 4
  • Fatma Sen
    • 5
  • Serkan Keskin
    • 6
  • Mahmut Muslumanoglu
    • 3
  • Hasan Karanlik
    • 7
  • Kamuran Arslan Ibis
    • 8
  • Seden Kucucuk
    • 8
  • Maktav Dincer
    • 9
  • Ekrem Yavuz
    • 10
  • Sitki Tuzlali
    • 11
    • 12
  • Atilla Soran
    • 13
  1. 1.Internal Medicine, Medical Oncology, Istanbul Medical Faculty, Department of Medical Oncology, Institute of OncologyIstanbul UniversityIstanbulTurkey
  2. 2.General Surgery, Istanbul Medical Faculty, Department of SurgeryIstanbul UniversityIstanbulTurkey
  3. 3.Istanbul Medical Faculty, Department of General SurgeryIstanbul UniversityIstanbulTurkey
  4. 4.Internal Medicine, Department of Medical OncologyMehmet Ali Aydinlar University HospitalIstanbulTurkey
  5. 5.Department of Medical OncologyAvrasya HospitalIstanbulTurkey
  6. 6.Internal Medicine, Department of Medical OncologyMemorial HospitalIstanbulTurkey
  7. 7.Department of Surgical OncologyIstanbul University, Institute of OncologyIstanbulTurkey
  8. 8.Istanbul Medical Faculty, Department of Radiation OncologyIstanbul University, Institute of OncologyIstanbulTurkey
  9. 9.Department of Radiation OncologyGayrettepe Florence Nightingale HospitalIstanbulTurkey
  10. 10.Istanbul Medical Faculty, Department of Pathology, Istanbul UniversityIstanbulTurkey
  11. 11.Tuzlali Private Pathology LaboratoryIstanbulTurkey
  12. 12.Istanbul University, Istanbul Medical Faculty, Department of PathologyIstanbulTurkey
  13. 13.Surgical OncologyMagee-Women’s Hospital, University of Pittsburgh Medical CentrePittsburghUSA

Personalised recommendations